Cargando…
A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postop...
Autores principales: | Ngu, Siew-Fei, Ngan, Hextan Y. S., Chan, Karen K. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511802/ https://www.ncbi.nlm.nih.gov/pubmed/36176748 http://dx.doi.org/10.20517/cdr.2022.12 |
Ejemplares similares
-
PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021) -
RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
por: Kramer, Claire JH, et al.
Publicado: (2023) -
To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following
First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021) -
Surgery including fertility-sparing treatment of GTD
por: Ngu, Siew-Fei, et al.
Publicado: (2021) -
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
por: Hurley, Rachel M, et al.
Publicado: (2021)